| human | Q5 |
| P496 | ORCID iD | 0000-0001-7813-9078 |
| P2038 | ResearchGate profile ID | Jeffrey-Gunter |
| P734 | family name | Gunter | Q37562149 |
| Gunter | Q37562149 | ||
| Gunter | Q37562149 | ||
| P735 | given name | Jeffrey | Q13028078 |
| Jeffrey | Q13028078 | ||
| P106 | occupation | researcher | Q1650915 |
| Q96609427 | 18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
| Q33740879 | 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons |
| Q64236106 | A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR |
| Q37533514 | A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity |
| Q37633577 | AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies |
| Q59565281 | Aberrant tau and amyloid pathology underlies 1H MR spectroscopic alterations in Alzheimer's disease and Lewy body disease |
| Q35686223 | Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease |
| Q40649206 | Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia |
| Q35598271 | Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span |
| Q35416696 | Age-related changes in the default mode network are more advanced in Alzheimer disease |
| Q38812890 | Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study |
| Q35073049 | Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study |
| Q35183555 | Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD |
| Q30481978 | Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies |
| Q37228160 | Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition |
| Q37291586 | Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity |
| Q36650399 | An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease |
| Q33927219 | Antemortem MRI findings associated with microinfarcts at autopsy |
| Q59565283 | Antemortem MRI findings associated with presence of microinfarcts at autopsy |
| Q34575415 | Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. |
| Q33627819 | Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women |
| Q36251868 | Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge |
| Q57464222 | Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration |
| Q100731406 | Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment |
| Q91605447 | Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia |
| Q100696114 | Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imaging-pathology study |
| Q92843396 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia |
| Q100509978 | Associations of Quantitative Susceptibility Mapping with Alzheimer's Disease Clinical and Imaging Markers |
| Q36827384 | Atrial fibrillation, cognitive impairment, and neuroimaging |
| Q30489846 | Atrophy rates accelerate in amnestic mild cognitive impairment |
| Q93376009 | Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods |
| Q37427402 | Automatic quality assessment in structural brain magnetic resonance imaging |
| Q92583591 | Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers |
| Q35327928 | Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images |
| Q37366280 | Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. |
| Q34247849 | Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease |
| Q36863815 | Brain injury biomarkers are not dependent on β-amyloid in normal elderly |
| Q41654719 | Brain structural changes following adaptive cognitive training assessed by Tensor-Based Morphometry (TBM). |
| Q55164200 | Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. |
| Q36841536 | Brain β-amyloid load approaches a plateau |
| Q104742435 | CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings |
| Q90065965 | Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity: The Mayo Clinic Study of Aging |
| Q36722181 | Cascading network failure across the Alzheimer's disease spectrum |
| Q90646389 | Cerebral microbleeds: Prevalence and relationship to amyloid burden |
| Q91259072 | Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition |
| Q46423062 | Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study |
| Q36577827 | Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech |
| Q38601321 | Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals |
| Q37313783 | Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD |
| Q37336528 | Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease |
| Q37348015 | Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients |
| Q33565800 | Comparison of phantom and registration scaling corrections using the ADNI cohort |
| Q55069493 | Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. |
| Q38692086 | Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements |
| Q114945773 | Deep learning-based brain age prediction in normal aging and dementia |
| Q38803637 | Defining imaging biomarker cut points for brain aging and Alzheimer's disease |
| Q34135742 | Dementia with Lewy bodies: basis of cingulate island sign |
| Q91838928 | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
| Q36305487 | Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings |
| Q37401996 | Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study |
| Q35219244 | Does MRI scan acceleration affect power to track brain change? |
| Q37185690 | Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? |
| Q59565222 | EARLY, BUT NOT ADVANCED, NEUROFIBRILLARY TANGLE PATHOLOGY OR AMYLOID-B PATHOLOGY SIGNIFICANTLY ASSOCIATES WITH ABNORMAL HIPPOCAMPAL SIZE IN COGNITIVELY NORMAL ELDERLY |
| Q34614543 | Early Alzheimer's disease neuropathology detected by proton MR spectroscopy |
| Q36763368 | Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study |
| Q36515294 | Effect of lifestyle activities on Alzheimer disease biomarkers and cognition |
| Q36205024 | Effects of MRI scan acceleration on brain volume measurement consistency |
| Q34989777 | Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement |
| Q37280188 | Effects of hormone therapy on brain structure: A randomized controlled trial |
| Q37576667 | Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia |
| Q91546700 | Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects |
| Q41654319 | Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum |
| Q34693191 | FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type |
| Q37164817 | Focal hemosiderin deposits and β-amyloid load in the ADNI cohort |
| Q91967302 | Frontal lobe 1H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers |
| Q53178603 | Gray matter volumetric changes with a challenging adaptive cognitive training program based on the dual n-back task |
| Q90907680 | Identification of Anonymous MRI Research Participants with Face-Recognition Software |
| Q31151984 | Image-based gradient non-linearity characterization to determine higher-order spherical harmonic coefficients for improved spatial position accuracy in magnetic resonance imaging |
| Q92866859 | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
| Q48616179 | Imaging measures predict progression in progressive supranuclear palsy |
| Q34064379 | Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics |
| Q64070285 | Investigation of white matter PiB uptake as a marker of white matter integrity |
| Q50422287 | Joint associations of β-amyloidosis and cortical thickness with cognition |
| Q91360661 | Linear vs volume measures of ventricle size: Relation to present and future gait and cognition |
| Q37398634 | Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease |
| Q35928408 | Longitudinal stability of MRI for mapping brain change using tensor-based morphometry |
| Q51763159 | Longitudinal tau PET in ageing and Alzheimer's disease. |
| Q37163305 | MRI and MRS predictors of mild cognitive impairment in a population-based sample |
| Q37265436 | MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies |
| Q33483479 | Measurement of MRI scanner performance with the ADNI phantom |
| Q37339974 | Methodological considerations for measuring rates of brain atrophy |
| Q41213431 | Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type |
| Q34650162 | Microbleeds in the logopenic variant of primary progressive aphasia |
| Q37170598 | Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology |
| Q104756263 | Mild Cognitive Impairment at Risk for Lewy Body Dementia |
| Q48090587 | Modeling trajectories of regional volume loss in progressive supranuclear palsy |
| Q91386704 | Neural correlates of domain-specific cognitive decline: The ARIC-NCS Study |
| Q36565857 | Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy |
| Q24630362 | Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics |
| Q21134508 | Non-stationarity in the "resting brain's" modular architecture |
| Q47905334 | Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. |
| Q59565234 | PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI |
| Q59565237 | PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI |
| Q34715043 | Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies |
| Q50584813 | Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. |
| Q37062727 | Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry |
| Q100949634 | Predicting future rates of tau accumulation on PET |
| Q96131509 | Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions |
| Q91882184 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework |
| Q92748350 | Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome |
| Q47692626 | Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom. |
| Q59565304 | Rates of atrophy differ across pathologically defined subtypes of Alzheimer's disease: A longitudinal MRI study |
| Q36101560 | Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials |
| Q40373871 | Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy |
| Q33581412 | Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration |
| Q91216161 | Recommendations towards standards for quantitative MRI (qMRI) and outstanding needs |
| Q59565308 | Regional and whole-brain atrophy rates in autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease |
| Q37652823 | Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies |
| Q36528669 | Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment |
| Q36070362 | Sample size calculations for clinical trials targeting tauopathies: a new potential disease target |
| Q37448226 | Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis |
| Q37181302 | Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease |
| Q36677361 | Shapes of the trajectories of 5 major biomarkers of Alzheimer disease |
| Q35948528 | Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease |
| Q30575373 | Standardization of analysis sets for reporting results from ADNI MRI data |
| Q101359654 | Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease |
| Q47987344 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum |
| Q24647259 | The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods |
| Q90006715 | The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes |
| Q34500103 | The evolution of primary progressive apraxia of speech |
| Q36841519 | Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women |
| Q48592254 | Tracking the development of agrammatic aphasia: A tensor-based morphometry study |
| Q35119603 | Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. |
| Q36667836 | Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study |
| Q33572446 | Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative |
| Q35119419 | Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly |
| Q92748372 | White matter hyperintensities: relationship to amyloid and tau burden |
| Q36736127 | White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration |
| Q35612090 | White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging |
| Q50618207 | White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. |
| Q35137502 | Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia |
| Q92162097 | β-Amyloid PET and neuropathology in dementia with Lewy bodies |
Search more.